Man­u­fac­tur­ers, in­dus­try groups com­ment on FDA’s con­trol over ni­trosamines in drug prod­ucts

Last year
Pharma
FDA+

J&J and Astel­las pile on two more bio­phar­ma in­dus­try law­suits over CMS drug price ne­go­ti­a­tions

Last year
Pharma
Law

Mar­ket­ingRx roundup: Genen­tech, Bris­tol My­ers lead Fast Com­pa­ny in­no­va­tors list; Re­al Chem­istry inks AI deal  

Last year
Pharma
Marketing

Af­ter year­long de­lay, FDA com­pletes in­spec­tion for No­var­tis, BeiGene's an­ti-PD-1 drug from Chi­na

Last year
R&D
FDA+

Ar­genx launch­es $750M of­fer­ing af­ter PhII da­ta drop

Last year
Financing

Meta’s new Threads: Is this a so­cial me­dia flash in the pan or re­al deal for phar­ma mar­keters?

Last year
Pharma
Marketing

Aridis to delist from Nas­daq; Bi­cy­cle clos­es $200M+ of­fer­ing

Last year
News Briefing

New York gene ther­a­py start­up Neu­ro­gene eyes $200M from Ne­oleukin Nas­daq swap

Last year
Startups
Deals

No­var­tis cuts PhII obe­si­ty can­di­date as it fi­nal­izes San­doz spin­off

Last year
R&D
Pharma

CRO Sy­neos Health did­n't hold up its end of the deal in en­roll­ment for FSD Phar­ma's tri­al, ar­bi­tra­tion pan­el finds

Last year
Outsourcing
Law

Pfiz­er, Flag­ship al­ly on a $100M cash launch of a drug dis­cov­ery ex­pe­di­tion

Last year
Deals
Bioregnum

Ex­clu­sive: Texas biotech rais­es $47M to move heart surgery drug in­to piv­otal study

Last year
Financing

Neumo­ra goes big with three PhI­II de­pres­sion stud­ies, new CEO from Ab­b­Vie’s C-suite

Last year
People
R&D

Bill Haney adds a match­ing $100,000 con­tri­bu­tion to Kris­ten Hege's ad­ven­tur­ous fundrais­er back­ing women sci­en­tists

Last year
Bioregnum

No­vo Nordisk inks re­search deal with RNA start­up with new de­liv­ery ap­proach

Last year
Deals
R&D

EMA to drug de­vel­op­ers on AI: Car­ry out thor­ough risk as­sess­ments

Last year
AI
Pharma

Om­ni­com Health Group re­brands net­work for the fu­ture with em­pha­sis on DE&I, da­ta

Last year
Pharma
Marketing

Bi­par­ti­san group of sen­a­tors seeks to elim­i­nate in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

Last year
FDA+
Law

FTC sues phar­ma da­ta gi­ant IQVIA to block pur­chase — and po­ten­tial ad­ver­tis­ing strong­hold

Last year
Pharma
Marketing

J&J's Ry­bre­vant-chemo com­bo shows pos­i­tive PFS da­ta in con­fir­ma­to­ry study

Last year
R&D
Pharma

EU prepar­ing for pos­si­ble an­tibi­ot­ic short­age in the win­ter

Last year
Pharma
Manufacturing

FDA ap­proves an­oth­er RSV op­tion, this time it's Sanofi and As­traZeneca’s an­ti­body drug for in­fants

Last year
Pharma
FDA+

No­var­tis to buy siR­NA de­vel­op­er DTx Phar­ma for up to $1B

Last year
Deals
R&D

Sanofi, Doud­na-found­ed Scribe Ther­a­peu­tics to tar­get sick­le cell dis­ease in new pact

Last year
Deals
Pharma
First page Previous page 310311312313314315316 Next page Last page
A service from the Financial Times